Abstract
Cytidine deaminase (CDA) is a pyrimidine salvage pathway enzyme that catalyzes the hydrolytic deamination of cytidine and deoxycytidine to their corresponding uracil nucleosides. CDA also catalyzes the inactivation of some chemotherapeutic nucleoside analogues such as cytosine arabinoside and gemcitabine. CDA 79A > C (K27Q, rs2072671) and 208G > A (A70T, rs60369023) were found to be associated either with clinical outcomes as well as with pharmacokinetics and toxicity of drugs administered to different subsets of patients. In this paper we reported two PCR-based methods for CDA 79A > C (K27Q) and 208G > A (A70T) genotyping and tested their feasibility using DNA extracted from whole blood as well as from buccal swabs. The aim of this study was also to assess the distribution of genotypic variants in a central Italy population. The allele frequencies were 56.3% (K*) and 43.7% (Q*) for K27Q and 100% (A*) and 0% (T*) for A70T. The genotype frequencies were 32.8% (K*/K*), 46.9% (K*/Q*) and 20.3% (Q*/Q*) for K27Q. The genotype frequencies did not deviate from Hardy–Weinberg equilibrium. The results were compared with those of other reported populations. They showed marked ethnic group differences.
This is a preview of subscription content, access via your institution.


References
Vincenzetti S, Cambi A, Neuhard J, Garattini E, Vita A (1996) Recombinant human cytidine deaminase: expression, purification, and characterization. Protein Expr Purif 8:247–253
Watanabe S, Uchida T (1996) Expression of cytidine deaminase in human solid tumors and its regulation by 1 alpha, 25-dihydroxyvitamin D3. Biochim Biophys Acta 1312:99–104
Ho DH, Frei E (1971) Clinical pharmacology of 1-beta-darabinofuranosyl cytosine. Clin Pharmacol Ther 12:944–954
Cacciamani T, Vita A, Cristalli G et al (1991) Purification of human cytidine deaminase: molecular and enzymatic characterization and inhibition by synthetic pyrimidine analogs. Arch Biochem Biophys 290:285–292
Chabner B (1990) Cytidine analogs. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principals and practice. JB Lippincott, New York, pp 152–179
Betts L, Xiang S, Short SA, Wolfenden R, Carter CW Jr (1994) Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. J Mol Biol 235:635–656
Schroder JK, Kirch C, Seeber S, Schutte J (1998) Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 103:1096–1103
Laliberte J, Momparler RL (1994) Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res 54:5401–5407
Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J (1998) Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 26:421–425
Kuhn K, Bertling WM, Emmrich F (1993) Cloning of a functional cDNA for human cytidine deaminase (CDD) and its use as a marker of monocyte/macrophage differentiation. Biochem Biophys Res Commun 190:1–7
Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL (2004) Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 4:307–314
Yonemori K, Ueno H, Okusaka T et al (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11:2620–2624
Yue L, Saikawa Y, Ota K, Tanaka M, Uehara T, Maeba H (2003) A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13:29–38
Gilbert JA, Salavaggione OE, Ji Y et al (2006) Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 12:1794–1803
Sugiyama E, Kaniwa N, Kim SR et al (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32–42
Chew HK, Doroshow JH, Frankel P et al (2009) Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 27:2163–2169
Bhatla D, Gerbing RB, Alonzo TA et al (2009) Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol 144:388–394
Giovannetti E, Laan AC, Vasile E et al (2008) Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 27:720–725
Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T et al (2003) A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13:29–38
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 11:1215
Walker AH, Najarian D, White DL, Jaffe JF, Kanetsky PA, Rebbeck TR (1999) Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ Health Perspect 107:517–520
Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE (2006) Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 119:276–283
Acknowledgment
This work was supported by Department of Morphological Science and Comparative Biochemistry, University of Camerino, Italy.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carpi, F.M., Vincenzetti, S., Micozzi, D. et al. PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population. Mol Biol Rep 37, 3363–3368 (2010). https://doi.org/10.1007/s11033-009-9923-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-009-9923-6
Keywords
- Cytidine deaminase (CDA)
- RFLP-PCR
- Single nucleotide polymorphism
- Genotyping assay
- Oncology
- Gemcitabine
- Ara-C